AAP
ORIC icon

Arax Advisory Partners’s Oric Pharmaceuticals ORIC Stock Holding History

Arax Advisory Partners’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.72K Sell
215
-71
-25% -$806 ﹤0.01% 3016
2025
Q4 		$2.34K Sell
286
-3,620
-93% -$41.7K ﹤0.01% 3205
2025
Q3 		$46.9K Buy
+3,906
New +$41.1K ﹤0.01% 1857
2025
Q1 		– Sell
-68
Closed -$549 – 2942
2024
Q4 		$549 Buy
+68
New +$624 ﹤0.01% 2310

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Arax Advisory Partners's ORIC Position: Q1 2026 in Review

Arax Advisory Partners reduced its Oric Pharmaceuticals (ORIC) stake by 25% in Q1 2026, selling an estimated $806 and leaving 215 shares worth $2.72K. The position accounts for ﹤0.01% of the portfolio, ranked #3016.

Arax Advisory Partners first reported a position in ORIC in Q4 2024 and has held it in 4 quarters since. The position peaked at $46.9K in Q3 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Arax Advisory Partners held 215 shares of Oric Pharmaceuticals worth $2.72K as of Q1 2026.
  • Arax Advisory Partners sold 71 Oric Pharmaceuticals shares in Q1 2026, an estimated $806.
  • Oric Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3016 holding.
  • Arax Advisory Partners first reported a position in Oric Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
  • Arax Advisory Partners's Oric Pharmaceuticals position peaked at $46.9K in Q3 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.